Facebook
Twitter
Telegram
Report an ErrorPDS Biotechnology Corporation Balance Sheet 2011-2024 | PDSB
Annual Balance Sheet PDS Biotechnology Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-73.4 M | -64.8 M | -28.2 M | -12.2 M | -34.6 M | -67.6 M | -91.4 M | -125 M | -10.9 M | -7.86 M | - | - | |
Long Term Debt |
123 K | 164 K | 231 K | - | - | - | 17.4 M | 15 M | 3.03 M | 2.53 M | - | - | - |
Long Term Debt Current |
- | 231 K | 259 K | 120 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 490 K | - | - | 17.4 M | 15 M | 3.03 M | 41 M | 22.3 M | - | - |
Total Current Liabilities |
13.6 M | 9.82 M | 3.76 M | 3.27 M | 2.79 M | 6.38 M | 12.9 M | 6.68 M | 8.59 M | - | - | - | - |
Total Liabilities |
33.3 M | 33 M | 3.99 M | 3.76 M | 2.79 M | 6.38 M | 30.2 M | 21.6 M | 11.6 M | 44.9 M | 24.1 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-145 M | -102 M | -60.7 M | -43.8 M | -28.9 M | -193 M | -152 M | -101 M | -62.3 M | -29.8 M | -16 M | - | - |
Total Assets |
59.4 M | 77 M | 67.2 M | 30.9 M | 14.5 M | 36.2 M | 92.6 M | 111 M | 134 M | 17 M | 8.73 M | - | - |
Cash and Cash Equivalents |
56.6 M | 73.8 M | 65.2 M | 28.8 M | 12.2 M | 34.6 M | 88.1 M | 106 M | 130 M | 13.7 M | 7.86 M | - | - |
Book Value |
26.1 M | 44 M | 63.2 M | 27.1 M | 11.7 M | 29.8 M | 62.4 M | 89.3 M | 122 M | -27.8 M | -15.3 M | - | - |
Total Shareholders Equity |
26.1 M | 44 M | 63.2 M | 27.1 M | 11.7 M | -2.07 M | 62.4 M | 89.3 M | 122 M | -27.8 M | -15.3 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet PDS Biotechnology Corporation
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
108 K | 123 K | 137 K | 152 K | 165 K | 164 K | 77.1 K | 59.6 K | 147 K | 231 K | 314 K | 395 K | 458 K | 490 K | 490 K | 490 K | 490 K | - | - | - | 903 K | - | - | - | - | - | - | - | - | - | 15 M | 4.36 M | 4.92 M | 5.47 M | 6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
31.8 M | 33.3 M | 32.7 M | 31.3 M | 27.4 M | 33 M | 27.8 M | 4.58 M | 5.17 M | 3.99 M | 3.89 M | 4.4 M | 3.39 M | 3.76 M | 3.76 M | 3.76 M | 3.76 M | 2.79 M | - | - | 2.79 M | 2.23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-155 M | -145 M | -134 M | -123 M | -111 M | -102 M | -82.4 M | -75 M | -69.2 M | -60.7 M | -54.4 M | -47.4 M | -46.8 M | -43.8 M | -43.8 M | -43.8 M | -43.8 M | -28.9 M | -28.9 M | -28.9 M | -28.9 M | -21.9 M | -21 M | -21 M | -21 M | -152 M | -152 M | -152 M | -152 M | -101 M | -101 M | -101 M | -101 M | -62.3 M | -62.3 M | -62.3 M | -62.3 M | -29.8 M | -29.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
69 M | 59.4 M | 57.2 M | 63.8 M | 68.4 M | 77 M | 74.9 M | 56 M | 61 M | 67.2 M | 71.7 M | 77.4 M | 27.8 M | 30.9 M | 30.9 M | 30.9 M | 30.9 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 164 K | 344 K | 344 K | 344 K | 92.6 M | 92.6 M | 92.6 M | 92.6 M | 111 M | 111 M | 111 M | 111 M | 134 M | 134 M | 134 M | 134 M | 16.8 M | 17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
66.6 M | 56.6 M | 54.3 M | 60.6 M | 65.2 M | 73.8 M | 71.6 M | 53 M | 58.9 M | 65.2 M | 69.7 M | 74.7 M | 25 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 104 K | 104 K | 104 K | 104 K | 88.1 M | 88.1 M | 88.1 M | 88.1 M | 106 M | 106 M | 106 M | 106 M | 130 M | 130 M | 130 M | 130 M | 13.7 M | 13.7 M | - | - | 7.86 M | - | - | - | - | - | - | - | 141 K | - | - | - |
Book Value |
37.2 M | 26.1 M | 24.5 M | 32.4 M | 41 M | 44 M | 47.1 M | 51.4 M | 55.9 M | 63.2 M | 67.9 M | 73 M | 24.4 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 11.7 M | 14.5 M | 14.5 M | 11.7 M | -2.07 M | 344 K | 344 K | 344 K | 92.6 M | 92.6 M | 92.6 M | 92.6 M | 111 M | 111 M | 111 M | 111 M | 134 M | 134 M | 134 M | 134 M | 16.8 M | 17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
37.2 M | 26.1 M | 24.5 M | 32.4 M | 41 M | 44 M | 47.1 M | 51.4 M | 55.9 M | 63.2 M | 67.9 M | 73 M | 24.4 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | -2.07 M | -1.7 M | -1.7 M | -1.7 M | -610 K | 62.4 M | 62.4 M | 62.4 M | 89.3 M | 89.3 M | 89.3 M | 89.3 M | 122 M | 122 M | 122 M | 122 M | -27.8 M | -27.8 M | - | - | -15.3 M | - | - | - | -7.65 M | - | - | - | - | - | - | - |
All numbers in USD currency